🚀 VC round data is live in beta, check it out!
Editas Medicine Valuation Multiples
Discover revenue and EBITDA valuation multiples for Editas Medicine and similar public comparables like Cereno Scientific, Mycenax Biotech, Heron Therapeutics, Searle Co. and more.
Editas Medicine Overview
About Editas Medicine
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Founded
2013
HQ
Employees
246
Website
Financials (LTM)
EV
$63M
Editas Medicine Financials
Editas Medicine reported last 12-month revenue of $38M and negative EBITDA of ($145M).
In the same LTM period, Editas Medicine generated $38M in gross profit, ($145M) in EBITDA losses, and had net loss of ($149M).
Revenue (LTM)
Editas Medicine P&L
In the most recent fiscal year, Editas Medicine reported revenue of $41M and EBITDA of ($149M).
Editas Medicine expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $38M | XXX | $41M | XXX | XXX | XXX |
| Gross Profit | $38M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($145M) | XXX | ($149M) | XXX | XXX | XXX |
| EBITDA Margin | (384%) | XXX | (367%) | XXX | XXX | XXX |
| EBIT Margin | (397%) | XXX | (245%) | XXX | XXX | XXX |
| Net Profit | ($149M) | XXX | ($160M) | XXX | XXX | XXX |
| Net Margin | (395%) | XXX | (395%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Editas Medicine Stock Performance
Editas Medicine has current market cap of $209M, and enterprise value of $63M.
Market Cap Evolution
Editas Medicine's stock price is $2.15.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $63M | $209M | 0.0% | XXX | XXX | XXX | $-1.64 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialEditas Medicine Valuation Multiples
Editas Medicine trades at 1.7x EV/Revenue multiple, and (0.4x) EV/EBITDA.
EV / Revenue (LTM)
Editas Medicine Financial Valuation Multiples
As of March 21, 2026, Editas Medicine has market cap of $209M and EV of $63M.
Equity research analysts estimate Editas Medicine's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Editas Medicine has a P/E ratio of (1.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $209M | XXX | $209M | XXX | XXX | XXX |
| EV (current) | $63M | XXX | $63M | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | (0.4x) | XXX | (0.4x) | XXX | XXX | XXX |
| EV/EBIT | (0.4x) | XXX | (0.6x) | XXX | XXX | XXX |
| EV/Gross Profit | 1.7x | XXX | — | XXX | XXX | XXX |
| P/E | (1.4x) | XXX | (1.3x) | XXX | XXX | XXX |
| EV/FCF | (0.4x) | XXX | (0.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Editas Medicine Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Editas Medicine Margins & Growth Rates
Editas Medicine's revenue in the last 12 month declined by (27%).
Editas Medicine's revenue per employee in the last FY averaged $0.2M.
Editas Medicine's rule of 40 is (411%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Editas Medicine's rule of X is (451%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Editas Medicine Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (27%) | XXX | (31%) | XXX | XXX | XXX |
| EBITDA Margin | (384%) | XXX | (367%) | XXX | XXX | XXX |
| EBITDA Growth | (29%) | XXX | (33%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (411%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (451%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 131% | XXX | 123% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 240% | XXX | 222% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 345% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Editas Medicine Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Cereno Scientific | XXX | XXX | XXX | XXX | XXX | XXX |
| Mycenax Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Heron Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Searle Co. | XXX | XXX | XXX | XXX | XXX | XXX |
| NeOnc | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Editas Medicine M&A Activity
Editas Medicine acquired XXX companies to date.
Last acquisition by Editas Medicine was on XXXXXXXX, XXXXX. Editas Medicine acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Editas Medicine
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialEditas Medicine Investment Activity
Editas Medicine invested in XXX companies to date.
Editas Medicine made its latest investment on XXXXXXXX, XXXXX. Editas Medicine invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Editas Medicine
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Editas Medicine
| When was Editas Medicine founded? | Editas Medicine was founded in 2013. |
| Where is Editas Medicine headquartered? | Editas Medicine is headquartered in United States. |
| How many employees does Editas Medicine have? | As of today, Editas Medicine has over 246 employees. |
| Who is the CEO of Editas Medicine? | Editas Medicine's CEO is Gilmore O’Neill. |
| Is Editas Medicine publicly listed? | Yes, Editas Medicine is a public company listed on Nasdaq. |
| What is the stock symbol of Editas Medicine? | Editas Medicine trades under EDIT ticker. |
| When did Editas Medicine go public? | Editas Medicine went public in 2016. |
| Who are competitors of Editas Medicine? | Editas Medicine main competitors are Cereno Scientific, Mycenax Biotech, Heron Therapeutics, Searle Co.. |
| What is the current market cap of Editas Medicine? | Editas Medicine's current market cap is $209M. |
| What is the current revenue of Editas Medicine? | Editas Medicine's last 12 months revenue is $38M. |
| What is the current revenue growth of Editas Medicine? | Editas Medicine revenue growth (NTM/LTM) is (27%). |
| What is the current EV/Revenue multiple of Editas Medicine? | Current revenue multiple of Editas Medicine is 1.7x. |
| Is Editas Medicine profitable? | No, Editas Medicine is not profitable. |
| What is the current EBITDA of Editas Medicine? | Editas Medicine has negative EBITDA and is not profitable. |
| What is Editas Medicine's EBITDA margin? | Editas Medicine's last 12 months EBITDA margin is (384%). |
| What is the current EV/EBITDA multiple of Editas Medicine? | Current EBITDA multiple of Editas Medicine is (0.4x). |
| What is the current FCF of Editas Medicine? | Editas Medicine's last 12 months FCF is ($161M). |
| What is Editas Medicine's FCF margin? | Editas Medicine's last 12 months FCF margin is (426%). |
| What is the current EV/FCF multiple of Editas Medicine? | Current FCF multiple of Editas Medicine is (0.4x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.